Chris Simon/LinkedIn
Mar 6, 2026, 15:09
Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
Chris Simon, President and Chief Executive Officer at Haemonetics, Member of Board of Directors at Sotera Health Company and AdvaMed, shared on LinkedIn:
”Excited to receive FDA clearance for Persona PLUS, our proprietary, patent‑protected plasma apheresis technology.
This next‑generation, donor‑centric innovation advances the NexSys PCS platform, designed to safely improve yield, speed, and donor satisfaction.
Persona PLUS is supported by data from a randomized clinical trial with 30,000 plus donations from approximately 3,000 donors and was developed with our customers for the benefit of patients worldwide, with a clear focus on IgG yield and lowering cost per gram.”
Stay updated with Hemostasis Today.
-
Jun 7, 2026, 18:25Nita Radhakrishnan: Every Child Cured Is a Reminder of What Can Be Achieved When We Work Together
-
Jun 7, 2026, 18:24Yvette Fairfax: Wiskott-Aldrich Gene Therapy Changes Immunity, but Affordability May Determine Survival
-
Jun 7, 2026, 18:21Gulab Makwana: Complete Guide to Clotting Factors – Understanding the Coagulation System
-
Jun 7, 2026, 18:15Chuhan Dong: Presenting My Research on Antibody-Mediated RBC Clearance at Canadian Blood Services
-
Jun 7, 2026, 18:11Abdul Mannan: Pencil Cells in IDA – Why Most, but Not All Cases Show Them
-
Jun 7, 2026, 16:12Amr Mohamed: Common Types of Anemia
-
Jun 7, 2026, 15:50Venkateshwarlu Bairi: AVEVA Hyderabad Supports Children Living with Thalassemia and Sickle Cell Conditions
-
Jun 7, 2026, 15:48José Antonio García Erce: Hemochromatosis and Blood Donation
-
Jun 7, 2026, 15:29Marc Scherlinger: Uncovering the Immuno-Inflammatory Functions of Platelets at EULAR 2026